Skip to content

Bausch Health Companies BHC Debt issued (Note 13)

Debt issued (Note 13) at other companies

Henry Schein logo
Henry ScheinHSIC
$57M-62.0%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's debt issued (note 13).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's debt issued (note 13)?
Bausch Health Companies (BHC) reported debt issued (note 13) of $2.8B in Q1 2026.
How has Bausch Health Companies's debt issued (note 13) changed year-over-year?
Bausch Health Companies's debt issued (note 13) increased by 5504.0% year-over-year, from $50M to $2.8B.
What is the long-term trend for Bausch Health Companies's debt issued (note 13)?
Over 4 years (2021 to 2025), Bausch Health Companies's debt issued (note 13) has grown at a 49.7% compound annual growth rate (CAGR), from $2.1B to $10.56B.